These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23687558)

  • 21. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
    Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
    J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARĪ“ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligands at Free Fatty Acid Receptor 1 (GPR40).
    Hara T
    Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.
    Tsuda N; Kawaji A; Sato T; Takagi M; Higashi C; Kato Y; Ogawa K; Naba H; Ohkouchi M; Nakamura M; Hosaka Y; Sakaki J
    Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of GPR40 Agonists for Type 2 Diabetes.
    Liu JJ; Wang Y; Ma Z; Schmitt M; Zhu L; Brown SP; Dransfield PJ; Sun Y; Sharma R; Guo Q; Zhuang R; Zhang J; Luo J; Tonn GR; Wong S; Swaminath G; Medina JC; Lin DC; Houze JB
    ACS Med Chem Lett; 2014 May; 5(5):517-21. PubMed ID: 24900872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
    Wang Y; Liu JJ; Dransfield PJ; Zhu L; Wang Z; Du X; Jiao X; Su Y; Li AR; Brown SP; Kasparian A; Vimolratana M; Yu M; Pattaropong V; Houze JB; Swaminath G; Tran T; Nguyen K; Guo Q; Zhang J; Zhuang R; Li F; Miao L; Bartberger MD; Correll TL; Chow D; Wong S; Luo J; Lin DC; Medina JC
    ACS Med Chem Lett; 2013 Jun; 4(6):551-5. PubMed ID: 24900707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role and Future of FFA1 as a Therapeutic Target.
    Ghislain J; Poitout V
    Handb Exp Pharmacol; 2017; 236():159-180. PubMed ID: 27807697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist.
    Agarwal S; Sasane S; Deshmukh P; Rami B; Bandyopadhyay D; Giri P; Giri S; Jain M; Desai RC
    ACS Med Chem Lett; 2016 Dec; 7(12):1134-1138. PubMed ID: 27994752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
    Plummer CW; Clements MJ; Chen H; Rajagopalan M; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Nolting AF; Orr R; Christensen M; Campeau LC; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Nargund R; Howard AD; Colletti SL
    ACS Med Chem Lett; 2017 Feb; 8(2):221-226. PubMed ID: 28197316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.
    Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q
    Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
    Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
    J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.
    Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H
    Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine.
    Kong D; Guo S; Yang Y; Guo B; Xie X; Hu W
    Bioorg Med Chem Lett; 2019 Mar; 29(6):848-852. PubMed ID: 30685095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.